Study to Evaluate the Safety, Phage Kinetics, and Efficacy of Inhaled AP-PA02 in Subjects With Non-Cystic Fibrosis Bronchiectasis and Chronic Pulmonary Pseudomonas Aeruginosa Infection

Prior treatment

• Recent changes in either the treatment regimen or initiation of treatment with: oral macrolides, hypertonic saline, mucolytics, bronchodilator medications, or oral corticosteroids
• Currently receiving treatment for active infection at any site

Other illness

• History of lung transplantation
• History of cystic fibrosis
• History of α1-antitrypsin deficiency
• History of primary or acquired immunodeficiency syndromes
• History of COPD
• History of pulmonary malignancy or any other malignancy requiring treatment
• History of hemoptysis

Lab values

• History of prolonged QT syndrome

Other

• Abnormal vital signs at Screening
• Recent significant weight loss
• Recent use of supplemental oxygen during the day while at rest
• Recent use of cigarettes, cigars, or pipes, or used tobacco or other nicotine source by vaping
• Female pregnant of breastfeeding

• ≥ 18 years old
• Body mass index (BMI) of ≥ 18 kg/m2
• Evidence of bronchiectasis per CT
• Evidence of chronic pulmonary Pseudomonas aeruginosa infection
• Willing to undergo sputum induction procedures at designated study visits, and willing to provide expectorated sputum samples at all other timepoints (for subjects who are able to expectorate)
• FEV1 ≥ 35% of predicted normal \[per Global Lung Function Initiative (GLI) standards\] at Screening
• For Cohort A: have not received chronic inhaled antipseudomonal antibiotics regimen for at least 3 months prior to Visit 1
• For Cohort B: have received chronic inhaled antipseudomonal antibiotics regimen for at least 3 months prior to Visit 1